AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 80 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $9,000 | -50.0% | 3,710 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $18,000 | -37.9% | 3,710 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $29,000 | +11.5% | 3,710 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $26,000 | -10.3% | 3,710 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $29,000 | 0.0% | 3,710 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $29,000 | +11.5% | 3,710 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $26,000 | -23.5% | 3,710 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $34,000 | +209.1% | 3,710 | +58.3% | 0.00% | +100.0% |
| Q1 2020 | $11,000 | 0.0% | 2,344 | +70.0% | 0.00% | – |
| Q4 2019 | $11,000 | 0.0% | 1,379 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $11,000 | +22.2% | 1,379 | 0.0% | 0.00% | – |
| Q2 2019 | $9,000 | -18.2% | 1,379 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $11,000 | +10.0% | 1,379 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $10,000 | -23.1% | 1,379 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $13,000 | -13.3% | 1,379 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $15,000 | – | 1,379 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $891,000 | 15.31% |
| Aisling Capital Management LP | 1,691,151 | $13,445,000 | 2.68% |
| GREAT POINT PARTNERS LLC | 900,000 | $7,155,000 | 1.67% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $22,639,000 | 1.40% |
| Altium Capital Management LP | 609,689 | $4,847,000 | 1.27% |
| Sio Capital Management, LLC | 446,000 | $3,546,000 | 1.13% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,953,000 | 1.12% |
| Samsara BioCapital, LLC | 883,720 | $7,026,000 | 1.10% |
| Lion Point Capital, LP | 300,000 | $2,385,000 | 0.45% |
| Abingworth LLP | 240,500 | $1,912,000 | 0.43% |